November 16, 2022 | Advocacy, Funding, Treatments
At the August 2022 meeting of PHARMAC’s Pharmacology and Therapeutics Advisory Committee (PTAC), Multiple Sclerosis NZ (MSNZ) made a submission in support of the funding of Siponimod (Mayzent) for Secondary Progressive MS. At this meeting PTAC recommended listing with low priority and have requested further advice from the […]
December 20, 2021 | Life with MS, MS Voice, Newsletter, Research, Treatments
My name is Celia Attwood, I’m 32 years old and a mum of 2 beautiful boys. I had been to see my G.P numerous times over the years before being diagnosed with MS but with no definite answers and […]